These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38548090)

  • 41. The resorptive apparatus of osteoclasts supports lysosomotropism and increases potency of basic versus non-basic inhibitors of cathepsin K.
    Fuller K; Lindstrom E; Edlund M; Henderson I; Grabowska U; Szewczyk KA; Moss R; Samuelsson B; Chambers TJ
    Bone; 2010 May; 46(5):1400-7. PubMed ID: 20097319
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats.
    Kim MK; Kim HD; Park JH; Lim JI; Yang JS; Kwak WY; Sung SY; Kim HJ; Kim SH; Lee CH; Shim JY; Bae MH; Shin YA; Huh Y; Han TD; Chong W; Choi H; Ahn BN; Yang SO; Son MH
    J Pharmacol Exp Ther; 2006 Aug; 318(2):555-62. PubMed ID: 16699068
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Reducing bone resorption by cathepsin K inhibitor and treatment of osteoporosis].
    Watanabe R; Okazaki R
    Clin Calcium; 2014 Jan; 24(1):59-67. PubMed ID: 24369281
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Advanced glycation end products biphasically modulate bone resorption in osteoclast-like cells.
    Li Z; Li C; Zhou Y; Chen W; Luo G; Zhang Z; Wang H; Zhang Y; Xu D; Sheng P
    Am J Physiol Endocrinol Metab; 2016 Mar; 310(5):E355-66. PubMed ID: 26670486
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Azanitrile Cathepsin K Inhibitors: Effects on Cell Toxicity, Osteoblast-Induced Mineralization and Osteoclast-Mediated Bone Resorption.
    Ren ZY; Machuca-Gayet I; Domenget C; Buchet R; Wu Y; Jurdic P; Mebarek S
    PLoS One; 2015; 10(7):e0132513. PubMed ID: 26168340
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interferon-gamma down-regulates gene expression of cathepsin K in osteoclasts and inhibits osteoclast formation.
    Kamolmatyakul S; Chen W; Li YP
    J Dent Res; 2001 Jan; 80(1):351-5. PubMed ID: 11269728
    [TBL] [Abstract][Full Text] [Related]  

  • 47. LRP1 Suppresses Bone Resorption in Mice by Inhibiting the RANKL-Stimulated NF-κB and p38 Pathways During Osteoclastogenesis.
    Lu D; Li J; Liu H; Foxa GE; Weaver K; Li J; Williams BO; Yang T
    J Bone Miner Res; 2018 Oct; 33(10):1773-1784. PubMed ID: 29750835
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cathepsin K activity-dependent regulation of osteoclast actin ring formation and bone resorption.
    Wilson SR; Peters C; Saftig P; Brömme D
    J Biol Chem; 2009 Jan; 284(4):2584-92. PubMed ID: 19028686
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Matrix-metalloproteinase-9 is cleaved and activated by cathepsin K.
    Christensen J; Shastri VP
    BMC Res Notes; 2015 Jul; 8():322. PubMed ID: 26219353
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys.
    Kumar S; Dare L; Vasko-Moser JA; James IE; Blake SM; Rickard DJ; Hwang SM; Tomaszek T; Yamashita DS; Marquis RW; Oh H; Jeong JU; Veber DF; Gowen M; Lark MW; Stroup G
    Bone; 2007 Jan; 40(1):122-31. PubMed ID: 16962401
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of miR-29 Activity in the Myeloid Lineage Increases Response to Calcitonin and Trabecular Bone Volume in Mice.
    Shin B; Hrdlicka HC; Delany AM; Lee SK
    Endocrinology; 2021 Oct; 162(10):. PubMed ID: 34192317
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cathepsin K deficiency in mice induces structural and metabolic changes in the central nervous system that are associated with learning and memory deficits.
    Dauth S; Sîrbulescu RF; Jordans S; Rehders M; Avena L; Oswald J; Lerchl A; Saftig P; Brix K
    BMC Neurosci; 2011 Jul; 12():74. PubMed ID: 21794126
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Different cysteine proteinases involved in bone resorption and osteoclast formation.
    Brage M; Abrahamson M; Lindström V; Grubb A; Lerner UH
    Calcif Tissue Int; 2005 Jun; 76(6):439-47. PubMed ID: 15906014
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identification of substrate-specific inhibitors of cathepsin K through high-throughput screening.
    Law S; Du X; Panwar P; Honson NS; Pfeifer T; Roberge M; Brömme D
    Biochem J; 2019 Feb; 476(3):499-512. PubMed ID: 30622151
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PP121 suppresses RANKL-Induced osteoclast formation in vitro and LPS-Induced bone resorption in vivo.
    Zhou Z; Chen X; Chen X; Qin A; Mao Y; Pang Y; Yu S; Zhang S
    Exp Cell Res; 2020 Mar; 388(2):111857. PubMed ID: 31972221
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Induction of Lrp5 HBM-causing mutations in Cathepsin-K expressing cells alters bone metabolism.
    Kang KS; Hong JM; Horan DJ; Lim KE; Bullock WA; Bruzzaniti A; Hann S; Warman ML; Robling AG
    Bone; 2019 Mar; 120():166-175. PubMed ID: 30409757
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular and cellular basis of bone resorption.
    Gruber R
    Wien Med Wochenschr; 2015 Feb; 165(3-4):48-53. PubMed ID: 25223736
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate.
    Stroup GB; Lark MW; Veber DF; Bhattacharyya A; Blake S; Dare LC; Erhard KF; Hoffman SJ; James IE; Marquis RW; Ru Y; Vasko-Moser JA; Smith BR; Tomaszek T; Gowen M
    J Bone Miner Res; 2001 Oct; 16(10):1739-46. PubMed ID: 11585335
    [TBL] [Abstract][Full Text] [Related]  

  • 59. RANK ligand and interferon gamma differentially regulate cathepsin gene expression in pre-osteoclastic cells.
    Pang M; Martinez AF; Jacobs J; Balkan W; Troen BR
    Biochem Biophys Res Commun; 2005 Mar; 328(3):756-63. PubMed ID: 15694411
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New Function of RUNX2 in Regulating Osteoclast Differentiation via the AKT/NFATc1/CTSK Axis.
    Xin Y; Liu Y; Liu D; Li J; Zhang C; Wang Y; Zheng S
    Calcif Tissue Int; 2020 May; 106(5):553-566. PubMed ID: 32008052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.